Authors
Ling Pan, Xilong Ren, Jiating Wang, Yunting Xiao, Liping Zhu, Xiya Zhang, Leqi Qian, Yejing Huang, Li Li, Heng Sun, Renkai Yang, Yi Liu, Xinfeng Wu, Hongsheng Wang, Dongqing Li
Published in
Proceedings of the National Academy of Sciences of the United States of America. Volume 123. Issue 35. Pages e2601536123. Epub Aug 27, 2026.
Abstract
Fibroblasts are heterogeneous stromal cells with remarkable lineage plasticity, generating distinct subsets that orchestrate either regenerative repair or fibrotic remodeling. However, how the pro-fibrotic fibroblast state is molecularly stabilized after activation remains poorly defined. Here, we identify the long noncoding RNA SNHG26 as an essential regulator of fibroblast fate maintenance and fibrogenic activity. SNHG26 is markedly enriched in CD90+ fibroblasts within human hypertrophic scars and keloids. Genetic deletion of Snhg26 in fibroblasts or antisense oligonucleotide-mediated silencing disrupts mesenchymal identity, suppresses extracellular matrix synthesis, and dramatically attenuates scar formation in murine and xenograft models. Single-cell transcriptomics reveal that loss of SNHG26 promotes a mesenchymal-to-papillary fibroblast transition, indicating that SNHG26 enforces lineage stability within the scar-forming fibroblast pool. Mechanistically, SNHG26 functions as a nuclear scaffold that binds the RNA-binding protein PTBP1, enabling PTBP1-directed alternative polyadenylation of AKT3. This interaction favors distal polyadenylation site usage, generating a long 3'UTR AKT3 isoform with enhanced stability, thereby sustaining AKT3 expression and downstream pro-fibrotic signaling. Upstream, TNFα-ERK-STAT3 signaling induces SNHG26 transcription, linking chronic inflammation to persistent posttranscriptional activation of fibrogenic pathways. Collectively, these findings define a lncRNA-based regulatory checkpoint in which the SNHG26-PTBP1-AKT3 axis stabilizes mesenchymal fibroblast identity and drives extracellular matrix accumulation. Targeting SNHG26 offers a promising therapeutic strategy for preventing pathological scar formation.
PMID:
42658765
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 19
- Comments 0